## Contents

### Editorials

713  
**Clinical Corner: a new feature in Menopause**  
Isaac Schiff, MD and Margery Gass, MD, NCMP

714  
**Endocrine therapy for breast cancer: a tough pill to swallow**  
Kerry L. Reynolds, MD and Michaela J. Higgins, MD, MRCPI

717  
**Staging reproductive aging: contemporary research applications of Staging Reproductive Aging Workshop and Staging Reproductive Aging Workshop + 10**  
Nancy Fugate Woods, PhD, RN, FAAN and Ellen Sullivan Mitchell, PhD

719  
**There is more to the relation between intraocular pressure and metabolic syndrome than meets the eye: a connection to estrogen deficiency**  
Louis R. Pasquale, MD, FARVO

### Original Articles

721  
**Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis**  
Robin J. Bell, MB, BS, PhD, MPH, FAFPHM, Max Schwarz, MB, BS, FRACP, FACP, FACHPM, Pamela Fradkin, MBBS, Penelope J. Robinson, BBiomedSci (Hons), M Biostat, and Susan R. Davis, MB, BS, PhD, FRACP

*The majority of women with hormone receptor positive breast cancer in Victoria Australia who have survived for nearly 6 years, are being treated according to current guidelines regarding oral adjuvant endocrine therapy, and have persisted with therapy, despite the adverse effects of estrogen depletion.*

(continued)
Classifying menopause stage by menstrual calendars and annual interviews: need for improved questionnaires
Pangaja Paramsothy, PhD, MPH, Siobán D. Harlow, PhD, Michael R. Elliott, PhD, Lynda D. Lisabeth, PhD, MPH, Sybil L. Crawford, PhD, and John F. Randolph Jr, MD
New questions need to be developed to accurately identify the start of the menopausal transition and should be evaluated in a multiethnic population with varying educational backgrounds.

Comparison of follicle-stimulating hormone, estradiol, ovarian volume, and antral follicle count, based on the Stages of Reproductive Aging Workshop system, among community-based women in China
Ning Sun, PhD, Shou-Qing Lin, BS, MD, Hui-Jun Lin, BS, Zhong He, PhD, Yan-Hong Wang, PhD, Ying Zhang, BS, Feng-Ling Chen, BS, and Ying Jiang, MS
These results suggest the existence of significant associations between FSH, E2, OV, AFC and menopausal status, supporting the STRAW reproductive system among community-based women in China.

Elevated intraocular pressure is associated with metabolic syndrome in postmenopausal women: the Korean National Health and Nutrition Examination Survey
Byoung-Jin Park, MD, Jin-Oh Park, MD, PhD, Hee-Taik Kang, MD, and Yong-Jae Lee, MD, MPH, PhD
In this cross-sectional study, elevated intraocular pressure is associated with metabolic syndrome in postmenopausal women, but not in premenopausal women. These findings suggest that intraocular pressure changes may be linked to metabolic syndrome in postmenopausal women.

Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women
Joo Hyun Park, MD, Ki Hyun Park, MD, PhD, SiHyun Cho, MD, Young Sik Choi, MD, Seok Kyo Seo, MD, Byung Seok Lee, MD, PhD, and Hoon Suk Park, MD
Improvement in lumbar bone mineral density and handgrip strength was observed with six months of alendronate and calcitriol combination therapy.
Spanish Menopause Society position statement: use of tibolone in postmenopausal women
Nicola´s Mendoza, MD, PhD, Pedro Abad, MD, PhD, Francesc Baró, MD, PhD, Ma Jesús Cancelo, MD, PhD, Plácido Llaneza, MD, PhD, Montserrat Manubens, MD, PhD, Francisco Quereda, MD, PhD, and Rafael Sánchez-Borrego, MD, PhD. 
Clinical recommendations and practical guidelines are provided for the use of tibolone in Spanish postmenopausal women.

Effects of adding alendronate to ongoing hormone therapy on bone mineral density in postmenopausal Korean women: a randomized, double-blind, placebo-controlled clinical trial
Yong-Ki Min, MD, PhD, Dong-Yun Lee, MD, PhD, Suk-Joo Choi, MD, PhD, Joo Han Kim, PhD, DooSeok Choi, MD, PhD, and Byung-Koo Yoon, MD, PhD. 
Addition of alendronate to ongoing hormone therapy for one year does not increase bone mineral density in postmenopausal Korean women with low bone mass.

A randomized, double-blind, controlled trial of a Chinese herbal formula (Er-Xian decoction) for menopausal symptoms in Hong Kong perimenopausal women
Linda L.D. Zhong, PhD, Yao Tong, PhD, Grace W.K. Tang, MD, Zhang Jin Zhang, PhD, Wai Ki Choi, RN, Kin Lok Cheng, BSc, Stephen C.W. Sze, PhD, Kun Wai, MSc, Qing Liu, PhD, and Ben X.B. Yu, PhD. 
This article investigated the effectiveness and safety of a Chinese herbal formula Er-Xian Decoction (EXD) in the treatment of menopausal symptoms in Hong Kong perimenopausal women. Results found that EXD was superior to placebo in reducing the frequency and severity of hot flushes and improving menopausal symptoms.

Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model
Kelly F. Ethun, DVM, PhD, Charles E. Wood, DVM, PhD, J. Mark Cline, DVM, PhD, Thomas C. Register, PhD, Susan E. Appt, DVM, and Thomas B. Clarkson, DVM. 
Bazedoxifene acetate given at a clinically relevant dose inhibits estrogen effects on the endometrium and lacks uterotropic effects when given alone.

Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats
Michael Feigh, MSc, Kim V. Andreassen, MSc, Sara T. Hjuler, MSc, Rasmus H. Nielsen, PhD, Claus Christiansen, MD, Kim Henriksen, PhD, and Morten A. Karsdal, PhD. 
This paper demonstrates a pronounced weight - and glucoregulatory efficacy of an oral formulation of salmon calcitonin in high-fat diet and ovariectomy-induced obese rats. These novel findings indicate the clinical usefulness of oral salmon calcitonin in postmenopausal obesity-related insulin resistance and type 2 diabetes.
Clinical Corner

Clinical Article

795
Androgen use for low sexual desire in midlife women
Susan R. Davis, MBBS, PhD

Patient Handout

e1
What You Should Know About Testosterone for Midlife Women With Sexual Problems

Erratum

798
Role of antimüllerian hormone as a biomarker of the menopausal transition:
Erratum